Skip to content

A UK Interventional Trial in Premature Infants With Apnea of Prematurity Using a Simple, Non-invasive Vibratory Device to Study the Effectiveness in Supporting Breathing and General Stability

WAVE Trial in Premature Infants With Apnea of Prematurity Using a Simple, Non-invasive Vibratory Device to Study the Effectiveness in Supporting Breathing and General Stability

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04528030
Acronym
WAVE
Enrollment
17
Registered
2020-08-27
Start date
2021-04-01
Completion date
2022-04-01
Last updated
2021-02-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Apnea of Newborn, Bradycardia Neonatal, Hypoxia Neonatal

Keywords

cardio-respiratory stability, neonate, premature infant, proprioceptive stimulation, Apnoea of Prematurity, Medical Device

Brief summary

Purpose of Study: Apnoea of Prematurity (AOP) is common, affecting the majority of infants born \<34 weeks gestational age (GA). Apnea is accompanied by intermittent hypoxia (IH), which contributes to multiple pathologies, including retinopathy of prematurity (ROP), sympathetic ganglia injury, impaired pancreatic islet cell and bone development, and neurodevelopmental disabilities. Standard of care for AOP/IH includes prone positioning, positive pressure ventilation, and caffeine therapy. The objective of this device is to provide an adjunct to current AoP treatment to support breathing in premature infants by using a simple, non-invasive vibratory device placed over limb proprioceptor fibers, an intervention using the principle that limb movements facilitate breathing. Methods Used: Premature infants (27+6 - 34+6 weeks GA) with clinical confirmed weeks with diagnosis of Apnoea of Prematurity. Caffeine therapy was not a reason for exclusion. Small vibration devices were placed on one hand and one foot and activated in a 6 hour ON/OFF sequence for a total of 24 hours. Heart rate, respiratory rate, oxygen saturation (SpO2), and breathing pauses were continuously collected.

Detailed description

Aim: To study the effect of (WAVE Device) limb proprioceptive stimulation using a vibratory device on AoP events, intermittent hypoxic episodes (SpO2≤85%) and bradycardias(≤100bpm) in a premature infant with confirmed clinical diagnosis of apnea of prematurity (AoP). The objective of the WAVE device is to provide an adjunct to current care to provide support in apnea of prematurity (AOP). Recurrent apnea and accompanying resultant intermittent hypoxic (IH) episodes are significant concerns commonly encountered in premature infants, and optimal management is a challenge to neonatologists. AoP is defined as \>20s breathing pause OR breathing pause of 10-20sec with clinical signs of Bradycardia (≤100bpm) and/or desaturation (≤85% SpO2) in infants born less than 37 weeks of gestation. When these pauses are longer (\> 20s), they are frequently prolonged by obstructed inspiratory efforts, most likely secondary to loss of upper airway tonic activity. In extremely low birth weight (ELBW) infants, the incidence of IH progressively increases over the first 4 weeks of postnatal life, followed by a plateau and subsequent decline between 6-8 weeks. The incidence of AOP correlates inversely with gestational age and birth weight. Nearly all infants born \<29 weeks gestation or \<1,000 g, 54% at 30 to 31 weeks, 15% at 32 to 33 weeks, and 7% at 34 to 35 weeks gestation exhibit AOP (2). Both animal and human evidence show that immature or impaired respiratory control and the resultant IH exposure contribute to a variety of pathophysiologic issues via pro-inflammatory and/or pro-oxidant cascade as well as cellular mechanisms, e.g., apoptosis, leading to acute and chronic morbidities (e.g. retinopathy of prematurity, altered growth and cardiovascular regulation, disrupting zinc homeostasis which hampers insulin production and there by predisposing to diabetes in later life, cerebellar injuries and neurodevelopmental disabilities). Current standard of care for AOP includes prone positioning, continuous positive airway pressure (CPAP) or nasal intermittent positive pressure ventilation (NIPPV) to prevent pharyngeal collapse and alveolar atelectasis, and methylxanthine therapy (caffeine, theophylline), which is the mainstay of treatment of central apnea. Apart from prone positioning, none of these interventions are optimal for early development. CPAP masks will distort the bony facial structure in early development, and methylxanthine interventions pose serious questions of neural development interactions.

Interventions

DEVICEWAVE device

WAVE applies a transcutaneous vibration to the soles of the foot and palms of the hand to elicit nerve signalling from pressure and other limb proprioceptor sensors to pontine, cerebellar, and medullary brain areas that coordinate limb movement and reflexively activate brain areas controlling breathing. The WAVE device is a battery-operated product to reduce the episodes of Apnoea of Prematurity by vibratory stimulation to the hand and foot.

Sponsors

Brighton and Sussex University Hospitals NHS Trust
CollaboratorOTHER
Inspiration Healthcare
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
DOUBLE (Investigator, Outcomes Assessor)

Masking description

The investigator analyzing the 4 cycles will not know whether it's an ON of OFF cycle during the 24 hour treatment period.

Intervention model description

Sequential Assignment In the same subject there were 2 periods: OFF cycles (6 hours x 2): 'No intervention' period (no vibrations) - two 6 hour epochs - total of 12 hours of 'No intervention' ON cycles (6hours x 2). Experimental period (with vibrations) - two 6 hour epochs - total of 12 hours of 'vibration intervention' In the same subjects cardio-respiratory parameters will be continuously monitored through the 24 hour treatment period of 4 cycles- heart rate, respiratory rate and oxygen saturation were compared during the experimental period (vibration) and during the no intervention period (no vibration).

Eligibility

Sex/Gender
ALL
Age
28 Weeks to 35 Weeks
Healthy volunteers
No

Inclusion criteria

* Written informed consent * Gestational age \> 27+6weeks, \< 34+1 weeks * Diagnosis of apnoea of prematurity (AOP) on clinical observations (atleast 4 AoP episodes and atleast one ABD event (equal and less 85% SpO2)- define clearly). * Caffeine treatment will not be an exclusion. If babies are on caffeine they need on maintenance dose for atleats 48 hours. (72hours after first dose of caffeine (Infant must be on maintenance dose) * During screening baby must demonstrate \>4 AoP/1 ABD events * Minimum 48 hours after extubation.

Exclusion criteria

* Inotropes * Infants with major congenital anomalies/malformations which will influence central nervous system and long-term outcomes in these infants, such as cardiac anomalies (except for Patent Ductus Arteriosus or Ventricular Septal Defect) or major neurological malformations, like meningoencephalocele, holoprosencephaly * Neonates who have apnoea from airway issues like laryngomalacia or tracheomalacia. * Neonates with a history of hypoxic-ischemic encephalopathy or Grade IV intraventricular haemorrhage * Infants that are currently intubated and invasive ventilation * Congenital skin malformations, skin conditions due to recurrent illness (microcirculation concerns). * Patients being treated for sepsis.

Design outcomes

Primary

MeasureTime frameDescription
Compare the cumulative burden of AoP with or without WAVE stimulation24 hoursThe primary objective is to compare the cumulative duration of breathing pauses related to Apnoea of Prematurity (AoP) between periods of presence and absence of tactile vibratory device stimulation as adjunct to standard care.

Secondary

MeasureTime frameDescription
Compare the number of AoP events.24 hoursTo compare the number of AoP events between periods of presence and absence of tactile vibratory device stimulation adjunct to standard of care.
Compare the number of desaturations (SpO2<86%) events24 hoursTo compare the number of desaturations (SpO2\<86%) events between periods of presence and absence of tactile vibratory device stimulation adjunct to standard of care.
Compare the cumulative depth of desaturations.24 hoursTo compare the cumulative depth of desaturations (SpO2\<86%) between periods of presence and absence of tactile vibratory device stimulation adjunct to standard of care.
Compare the cumulative duration of desaturations (SpO2<86%) events.24 hoursTo compare the cumulative duration of desaturations (SpO2\<86%) between periods of presence and absence of tactile vibratory device stimulation adjunct to standard of care.
Compare the cumulative depth of bradycardia events.24 hoursTo compare the cumulative depth of bradycardia events between periods of presence and absence of tactile vibratory device stimulation adjunct to standard of care.
Compare the cumulative duration of bradycardia events.24 hoursTo compare the cumulative duration of bradycardia events between periods of presence and absence of tactile vibratory device stimulation adjunct to standard of care.
Nursing assessment scores -NPASS scoring system (6).24 hoursTo compare NPASS scores (6) between periods of presence and absence of tactile vibratory device stimulation adjunct to standard of care.
Compare the number of bradycardia events.24 hoursTo compare the number of bradycardia events between periods of presence and absence of tactile vibratory device stimulation adjunct to standard of care.

Other

MeasureTime frameDescription
Post trial feedbackup to 24 weeksTo conduct post-trial surveys to gather feedback from bedside nurses and parents/legal guardians.

Contacts

Primary ContactJacqueline van Druten, BScMedHons
jacqueline.vandruten@inspiration-healthcare.com07407614698
Backup ContactR, A
CRR-WAVE@inspiration-healthcare.com

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026